



Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data

RESEARCH LETTER

ubiquity press

SANG GUNE K. YOO

GRACE S. CHUNG

SILVER K. BAHENDEKA

ABLA M. SIBAI

ALBERTINO DAMASCENO

FARSHAD FARZADFAR

PETER ROHLOFF

CORINE HOUEHANOU

BOLORMAA NOROV

KHEM B. KARKI

MOHAMMADREZA AZANGOU-KHYAVY

MAJA E. MARCUS

KRISHNA K. ARYAL

LUISA C. C. BRANT

MICHAELA THEILMANN

RENATA CÍFKOVÁ

NUNO LUNET

MONGAL S. GURUNG

JOSEPH KIBACHIO MWANGI

JOAO MARTINS

ROSA HAGHSHENAS

LELA STURUA

SEBASTIAN VOLLMER

TILL BÄRNIGHAUSEN

RIFAT ATUN

JEREMY B. SUSSMAN

KAVITA SINGH

SAHAR SAEEDI MOGHADDAM

DAVID GUWATUDDE

PASCAL GELDSETZER

JENNIFER MANNE-GOEHLER

MARK D. HUFFMAN

JUSTINE I. DAVIES

DAVID FLOOD

CORRESPONDING AUTHOR:

Sang Gune K. Yoo, MD

Washington University School of Medicine, John T. Milliken Department of Internal Medicine, Cardiovascular Division, 660 S. Euclid Ave, MSC 8086-43-13, St. Louis, MO 63100, USA

skyoo@wustl.edu

KEYWORDS:

cardiovascular disease; prevention; aspirin; non-communicable disease

TO CITE THIS ARTICLE:

Yoo SGK, Chung GS, Bahendeka SK, Sibai AM, Damasceno A, Farzadfar F, Rohloff P, Houehanou C, Norov B, Karki KB, Azangou-Khyavy M, Marcus ME, Aryal KK, Brant LCC, Theilmann M, Cífková R, Lunet N, Gurung MS, Mwangi JK, Martins J, Haghsheenas R, Sturua L, Vollmer S, Bärnighausen T, Atun R, Sussman JB, Singh K, Moghaddam SS, Guwatudde D, Geldsetzer P, Manne-Goehler J, Huffman MD, Davies JI, Flood D. Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data. *Global Heart*. 2024; 19(1): 44. DOI: <https://doi.org/10.5334/gh.1323>

*Author affiliations can be found in the back matter of this article

The role of aspirin in the primary prevention of atherosclerotic cardiovascular disease (CVD) is not clear, with recent clinical trials evaluating aspirin for primary prevention demonstrating both modest benefits and risks associated with its use [1]. Aspirin is not routinely recommended for primary prevention of CVD. Understanding patterns of aspirin use can inform strategies to promote guideline-concordant therapy, including de-implementation strategies to reduce unnecessary aspirin use. This study seeks to provide an updated estimate of worldwide aspirin use for primary prevention of CVD.

METHODS

We analyzed pooled individual-participant data from nationally representative health surveys conducted in 49 countries between 2013 and 2020. Details of the study design, data sources, and sample population have been described (Figure 1) [2].




Figure 1 A) Survey inclusion flow chart. HPACC refers to The GHP Project on Access to Care for Cardiometabolic Diseases Collaboration. STEPS refers to STEPwise approach to NCD risk factor surveillance surveys. **B)** Use of aspirin for primary prevention of cardiovascular disease by income group, age, sex, education, and rurality. Estimates are weighted by each country's 2019 population of individuals aged 40 to 69 years. Income group refers to World Bank per capita income categories in the year the survey was conducted. ^aEducation was unavailable in the survey from Tokelau. ^bUrban vs rural residence was unavailable in the surveys from Bermuda, Botswana, Brunei, Ecuador, Eswatini, Kiribati, Kuwait, Lebanon, Myanmar, Nauru, Solomon Islands, Sri Lanka, St Vincent and the Grenadines, Tajikistan, Timor-Leste, Tokelau, Tuvalu, and the US. **C)** CVD risk categories of individuals using aspirin for primary prevention by income group. Estimates are weighted by each country's 2019 population of individuals aged 40 to 69 years. Income group refers to World Bank per capita income categories in the year the survey was conducted. Categories of 10-year predicted CVD risk are calculated using the 2019 regionally calibrated WHO laboratory-based risk-prediction models.

The primary outcome was the use of aspirin for primary prevention of CVD. We defined primary prevention as the population without a self-reported history of myocardial infarction, stroke, or angina. We classified participants using aspirin for primary prevention into categories based on 10-year predicted CVD risk: <5%, 5–10%, 10–20%, and >20%, aligning with established guidelines [1]. The analysis used the 2019 regionally calibrated WHO laboratory-based risk-prediction models, which includes input variables of age, sex, smoking status, systolic blood pressure, history of diabetes, and total cholesterol [3].

We estimated the proportion of individuals using aspirin for the primary prevention of CVD by World Bank per-capita income categories [4]. We accounted for the complex survey design in analyses and used sampling weights rescaled in proportion to each country's 2019 population. We conducted our analysis in Stata version 17.0 (StataCorp) and R version 4.2.2 (R Foundation). Our study was considered exempt from regulation by the institutional review board at the University of Michigan (HUM00201307).

RESULTS

The dataset encompassed 96,914 individuals from 49 countries, with 88,340 categorized as belonging to the primary prevention group (Figure 1). Among individuals without a self-reported history of CVD, aspirin use in the overall pooled sample was 9.2% (95% CI: 8.4%–10.0%). The prevalence of aspirin use varied significantly by income group, with estimates of 0.6% (95% CI: 0.4%–0.8%) in low-income countries, 1.2% (95% CI: 1.1%–1.4%) in lower-middle-income countries, 11.7% (95% CI: 11.2%–12.2%) in upper-middle-income countries, and 17.7% (95% CI: 15.9%–19.6%) in high-income countries (Figure 1).

A substantial proportion of individuals in higher-income countries who used aspirin for primary prevention had low predicted CVD risk. For example, among those using aspirin for primary prevention in high-income countries, 59.6% (95% CI: 55.3%–63.7%) had 10-year CVD risk less than 10% (Figure 1). The median 10-year CVD risk among individuals using aspirin for primary prevention in high-income countries was 6.2% (IQR: 3.3%–10.2%).

DISCUSSION

In a diverse sample of nationally representative surveys conducted between 2013–2020, we found many people using aspirin for primary CVD prevention across the world. Particularly in upper-middle-income and high-income countries, people using aspirin for primary CVD prevention have low CVD risk. This study offers the most extensive and contemporary understanding of global aspirin use among individuals without a prior history of CVD. The finding is in contrast to evidence that questions the routine use of aspirin in populations effectively managed with cholesterol and blood pressure-lowering medications [5]. A modeling study suggested that primary prevention aspirin users who are at low risk or aged greater than 60 years experience minimal or even negative lifetime net benefit as measured by quality-adjusted life-years and total life-years [6]. In this context, the current study suggests overuse of aspirin among populations without a history of CVD is an important worldwide public health problem with particular salience in upper-middle-income and high-income countries where resources may be limited and greater health system efficiency could be achieved. However, the use of aspirin for primary prevention should be contextualized within individual health systems, considering factors such as population-level CVD risk and the accessibility of cholesterol and blood pressure-lowering medications and aspirin.

Limitations of the study include the use of self-reported data on aspirin use and CVD history and the incorporation of some surveys completed before the release of recent aspirin primary prevention trials. Nevertheless, the data remain relevant, as it takes decades for medical practices to change with the evolving evidence regarding the role of aspirin in prevention [7]. Additionally, it was not possible to define with certainty whether an individual's aspirin use was appropriate. For primary prevention, we assumed individuals to be at low CVD risk using a 10-year threshold of <10%. Finally, the 2019 WHO CVD risk equations used in our analysis are the most updated risk-prediction model for worldwide use, but the models have not been externally validated in all countries, given a paucity of CVD cohorts outside of high-income countries.

CONCLUSIONS

Aspirin use for primary prevention varies widely globally. Strategies aimed at de-prescribing aspirin in populations unlikely to benefit should be developed, evaluated, and implemented to mitigate the potential harms associated with unnecessary aspirin use.

FUNDING INFORMATION

PG is a Chan Zuckerberg Biohub – San Francisco investigator. LB was supported in part by CNPq 307329/2022-4. DF was supported by the NHLBI (award number K23HL161271), the Michigan Center for Diabetes Translational Research (award number P30DK092926), the University of Michigan Claude D. Pepper Older Americans Independence Center (award number 5P30 AG024824), and the University of Michigan Caswell Diabetes Institute Clinical Translational Research Scholars Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHOR CONTRIBUTIONS

Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

AUTHOR AFFILIATIONS

Sang Gune K. Yoo, MD  orcid.org/0009-0003-8281-0743

Cardiovascular Division, Department of Internal Medicine, Washington University in St Louis, St Louis, MO, USA

Grace S. Chung, PhD  orcid.org/0000-0002-1818-0148

Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

Silver K. Bahendeka, MD

Department of Internal Medicine, MKPGMS Uganda Martyrs University, Kampala; St Francis Hospital, Nsambya, Kampala, Uganda

Abla M. Sibai, PhD  orcid.org/0000-0002-1851-5606

Epidemiology and Population Health Department, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon

Albertino Damasceno, PhD  orcid.org/0000-0003-0925-494X

Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique; Nucleo de Investigação, Departamento de Medicina, Hospital Central do Maputo, Maputo Mozambique

Farshad Farzadfar, MD

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Peter Rohloff, MD

Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala; Division of Global Health Equity, Brigham and Women's Hospital; Boston, MA, USA

Corine Houehanou, MD

Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin

Bolormaa Norov, MD  orcid.org/0000-0001-8074-9393

Nutrition Department, National Center for Public Health, Ulaanbaatar, Mongolia

Khem B. Karki, MBBS

Department of Community Medicine and Public Health, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal

Mohammadreza Azangou-Khyavy, MD

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Maja E. Marcus, PhD  orcid.org/0000-0003-4904-2087

Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Krishna K. Aryal, PhD  orcid.org/0000-0003-0801-0775

Bergen Centre for Ethics and Priority Setting in Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; Public Health Promotion and Development Organization, Kathmandu, Nepal

Luisa C. C. Brant, MD  orcid.org/0000-0002-7317-1367

Departamento de Clínica Médica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Telehealth Center, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Michaela Theilmann, MA

Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany; Professorship of Behavioral Sciences in Prevention and Care, Technical University of Munich, Germany

Renata Cífková, MD  orcid.org/0000-0003-2765-3821

Center for Cardiovascular Prevention, First Faculty of Medicine and Thomayer University Hospital, Charles University in Prague, Prague, Czechia; Department of Medicine II, First Faculty of Medicine, Charles University in Prague, Prague, Czechia

Nuno Lunet, PhD

Department of Public Health and Forensic Health Sciences and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal; EPIUnit – Institute of Public Health, University of Porto, Porto, Portugal; ITR – Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal

Mongal S. Gurung, PhD  orcid.org/0000-0001-6481-6242

Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan

Joseph Kibachio Mwangi, MD

Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya; The Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland

Joao Martins, PhD

Faculty of Medicine and Health Sciences, Universidade Nacional Timor Lorosa'e, Dili, Timor-Leste

Rosa Haghsheenas, DBA

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Lela Sturua, PhD  orcid.org/0000-0002-8242-1145

Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia; Professor, Public Health Department, Petre Shotadze Tbilisi Medical Academy, Georgia

Sebastian Vollmer, PhD

Department of Economics & Centre for Modern Indian Studies, University of Goettingen, Göttingen, Germany

Till Bärnighausen, MD

Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany; Harvard Center for Population and Development Studies, Harvard University, Cambridge, USA; Africa Health Research Institute, Somkhele and Durban, South Africa

Rifat Atun, MD  orcid.org/0000-0002-1531-5983

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA

Jeremy B. Sussman, MD

Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA

Kavita Singh, PhD

Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany; Centre For Chronic Disease Control, New Delhi, India

Sahar Saeedi Moghaddam, MSc  orcid.org/0000-0002-3112-9179

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Kiel Institute for the World Economy, Kiel, Germany

David Guwatudde, PhD

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, Kampala, Uganda

Pascal Geldsetzer, ScD  orcid.org/0000-0002-8878-5505

Division of Primary Care and Population Health, Stanford University, USA; Chan Zuckerberg Biohub – San Francisco, San Francisco, California, USA

Jennifer Manne-Goehler, MD

Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

REFERENCES

1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. *Circulation*. 2019; 140: e596–646. DOI: <https://doi.org/10.1161/CIR.0000000000000678>
2. Yoo SGK, Chung GS, Bahendeka SK, Sibai AM, Damasceno A, Farzadfar F, et al. Aspirin for secondary prevention of cardiovascular disease in 51 low-, middle-, and high-income countries. *JAMA*. 2023; 330: 715–24. DOI: <https://doi.org/10.1001/jama.2023.12905>
3. The WHO CVD Risk Chart Working Group, Kaptoge S, Pennells L, Bacquer DD, Cooney MT, Kavousi M, et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. *Lancet Global Health*. 2019; 7: e1332–45. DOI: [https://doi.org/10.1016/S2214-109X\(19\)30318-3](https://doi.org/10.1016/S2214-109X(19)30318-3)
4. The World Bank. World Bank Country and Lending Groups n.d. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> (accessed January 18, 2023).
5. Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, et al. Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients. *Circulation*. 2017; 135: e793–813. DOI: <https://doi.org/10.1161/CIR.0000000000000467>
6. Dehmer SP, O'Keefe LR, Evans CV, Guirguis-Blake JM, Perdue LA, Maciosek MV. Aspirin use to prevent cardiovascular disease and colorectal cancer. *JAMA*. 2022; 327: 1598–607. DOI: <https://doi.org/10.1001/jama.2022.3385>
7. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: Understanding time lags in translational research. *Journal of the Royal Society of Medicine*. 2011; 104: 510–20. DOI: <https://doi.org/10.1258/jrsm.2011.110180>

TO CITE THIS ARTICLE:

Yoo SGK, Chung GS, Bahendeka SK, Sibai AM, Damasceno A, Farzadfar F, Rohloff P, Houehanou C, Norov B, Karki KB, Azangou-Khyavy M, Marcus ME, Aryal KK, Brant LCC, Theilmann M, Cifková R, Lunet N, Gurung MS, Mwangi JK, Martins J, Haghshenas R, Sturua L, Vollmer S, Bärnighausen T, Atun R, Sussman JB, Singh K, Moghaddam SS, Guwatudde D, Geldsetzer P, Manne-Goehler J, Huffman MD, Davies JI, Flood D. Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data. *Global Heart*. 2024; 19(1): 44. DOI: <https://doi.org/10.5334/gh.1323>

Submitted: 30 March 2024

Accepted: 16 April 2024

Published: 03 May 2024

COPYRIGHT:

© 2024 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See <http://creativecommons.org/licenses/by/4.0/>.

Global Heart is a peer-reviewed open access journal published by Ubiquity Press.